期刊
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
卷 63, 期 5, 页码 -出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.00014-19
关键词
HIV treatment; HIV-2; West Africa; antiretroviral therapy; bictegravir; drug resistance; human immunodeficiency virus; integrase
资金
- National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIH/NIAID) [2R01-AI060466, R01-AI120765]
- UW Center for AIDS Research (CFAR, NIH) [P30 AI027757]
- UW Royalty Research Fund [A92723]
- NIH
- University of Washington
- Bill and Melinda Gates Foundation
- Gilead Sciences
- Alere Technologies
- Merck Co., Inc.
- Janssen Pharmaceutica
- Cerus Corporation
- ViiV Healthcare
- Abbott Molecular Diagnostics
- Mary Gates Endowment for Students, University of Washington
- NIH/NIAID
- France Recherche Nord & Sud Sida-HIV Hepatites (ANRS)
We compared the activity of the integrase inhibitor bictegravir against HIV-1 and HIV-2 using a culture-based, single-cycle assay. Values of 50% effective concentrations ranged from 1.2 to 2.5 nM for 9 HIV-1 isolates and 1.4 to 5.6 nM for 15 HIV-2 isolates. HIV-2 integrase mutants G140S/Q148R and G140S/Q148H were 34- and 110-fold resistant to bictegravir, respectively; other resistance-associated mutations conferred <= 5-fold changes in bictegravir susceptibility. Our findings indicate that bictegravir-based antiretroviral therapy should be evaluated in HIV-2-infected individuals.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据
分享论文
